Cempra Inc (CEMP) was Initiated by Raymond James to “Outperform” and the brokerage firm has set the Price Target at $32. Raymond James advised their investors in a research report released on Sep 13, 2016.
Many Wall Street Analysts have commented on Cempra Inc. Shares were Reiterated by Jefferies on Aug 2, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .JP Morgan Initiated Cempra Inc on Jul 12, 2016 to “Overweight”, Price Target of the shares are set at $31.Shares were Reiterated by Stifel on Jun 24, 2016 to “Buy” and Lowered the Price Target to $ 47 from a previous price target of $51 .
On the company’s financial health, Cempra Inc reported $-0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 1, 2016. Analyst had a consensus of $-0.66. The company had revenue of $3.40 million for the quarter, compared to analysts expectations of $3.88 million. The company’s revenue was down -33.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.57 EPS.
Cempra Inc opened for trading at $21.5 and hit $22.74 on the upside on Monday, eventually ending the session at $22.65, with a gain of 5.30% or 1.14 points. The heightened volatility saw the trading volume jump to 650,538 shares. Company has a market cap of $1,178 M.
In a different news, on Mar 2, 2016, David Moore (Chief Commercial Officer) purchased 500 shares at $16.18 per share price. According to the SEC, on Jan 6, 2016, Dov A Md Goldstein (director) sold 842 shares at $30.07 per share price. On Dec 15, 2015, David W. Oldach (Chief Medical Officer) sold 10,000 shares at $30.17 per share price, according to the Form-4 filing with the securities and exchange commission.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product solithromycin is being developed in oral capsules intravenous or IV and suspension formulations initially for the treatment of community acquired bacterial pneumonia or CABP an infection of the respiratory tract. The Company’s second product is Taksta an antibiotic known as fusidic acid that has been used for decades outside the United States including Western Europe but which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.